Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Core Insights - Helus Pharma's shares declined following the announcement of topline results from a Phase 2 study for HLP004, a potential treatment for generalized anxiety disorder (GAD) [1] Anxiety Disorder Data - The Phase 2 study involved 36 patients who were randomized to receive either HLP004 or a placebo, showing a 10.4-point improvement in anxiety symptoms beyond standard care treatments [2] - The drug demonstrated a favorable tolerability profile with no serious adverse events or suicidality-related safety signals [2] Helus Pharma Drug Shows Durable Remission - At six months, the study population had 67% responders and 39% remitters [3] - In the 20 mg dosing arm, 59% met the criteria for response and 32% for remission, while the 2 mg arm had a 30% responder and remitter rate at week 6 [3] Competition - AtaiBeckley Inc. reported topline results from a Phase 2a trial of EMP-01 for Social Anxiety Disorder, with 49% of patients rated as "very much improved" or "much improved," compared to 15% in the placebo group [4] Helus Pharma's Technical Analysis - The stock is trading 10.43% below its 20-day simple moving average (SMA) and 12.5% below its 100-day SMA, indicating a bearish trend [5] - Over the past 12 months, shares have decreased by 5.2% and are closer to their 52-week lows than highs [5] Additional Technical Indicators - The RSI is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure [6] HELP Price Action - Helus Pharma shares were down 33.19% at $6.41 at the time of publication, with key resistance at $8.00 and key support at $7.50 [7]